Boehringer Ingelheim to cap asthma inhaler out-of-pocket costs at $35; Novo Nordisk’s obesity pill bests Wegovy in early trial

Taking stock of the drug industry, from the lab to the medicine chest

March 7, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Boehringer Ingelheim to cap asthma inhaler out-of-pocket costs at $35 The move comes not long after Sen. Bernie Sanders (I-Vt.) and other lawmakers opened a probe into asthma inhaler pricing. By Ed Silverman STAT+ | Novo Nordisk's obesity pill bests Wegovy in early trial In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the oral medicine amycretin. By Allison DeAngelis STAT+ | A deep dive into Applied Therapeutics' data, and questions on Cassava's erased data This week a deep dive into the bull and bear sides of the Applied Therapeutics debate, and another well-deserved swipe at Cassava Sciences. By Adam Feuerstein NIH via AP RSV monoclonal Beyfortus was 90% effective at preventing hospitalizations in children this winter: CDC Beyfortus, a new shot for RSV, was 90% effective at preventing hospitalizations in children, new data shows. By Helen Branswell

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser